Cable Car Capital LP Purchases New Position in ImageneBio, Inc. $IMA

Cable Car Capital LP purchased a new stake in ImageneBio, Inc. (NASDAQ:IMA) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 781,599 shares of the company’s stock, valued at approximately $4,611,000. Cable Car Capital LP owned approximately 0.07% of ImageneBio as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Blue Owl Capital Holdings LP acquired a new stake in shares of ImageneBio during the second quarter worth approximately $5,414,000. Deep Track Capital LP bought a new stake in ImageneBio during the 3rd quarter worth approximately $7,160,000. Vanguard Group Inc. bought a new stake in ImageneBio during the 3rd quarter worth approximately $1,902,000. BML Capital Management LLC increased its holdings in ImageneBio by 13.4% during the 1st quarter. BML Capital Management LLC now owns 200,730 shares of the company’s stock valued at $1,004,000 after purchasing an additional 23,704 shares in the last quarter. Finally, BlackRock Inc. acquired a new stake in ImageneBio during the 2nd quarter valued at $797,000. 75.00% of the stock is owned by institutional investors.

ImageneBio Price Performance

Shares of ImageneBio stock opened at $5.55 on Wednesday. The firm has a market cap of $62.99 million, a P/E ratio of -1.21 and a beta of 0.76. The firm has a 50 day simple moving average of $5.79 and a 200 day simple moving average of $5.83. ImageneBio, Inc. has a fifty-two week low of $3.94 and a fifty-two week high of $14.00.

ImageneBio (NASDAQ:IMA) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.63) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.90) by $0.27. On average, sell-side analysts expect that ImageneBio, Inc. will post -3.23 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have commented on IMA shares. HC Wainwright began coverage on ImageneBio in a research note on Friday. They issued a “buy” rating and a $28.00 price objective on the stock. Wedbush restated an “underperform” rating on shares of ImageneBio in a research note on Monday, May 11th. Weiss Ratings restated a “sell (e+)” rating on shares of ImageneBio in a research note on Monday, June 29th. Finally, Wall Street Zen cut ImageneBio from a “sell” rating to a “strong sell” rating in a report on Sunday, May 17th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $29.00.

Trending Headlines about ImageneBio

Here are the key news stories impacting ImageneBio this week:

• Positive Sentiment: HC Wainwright initiated research coverage with a Buy rating and a $28 price target, substantially above the stock’s recent trading level. The firm expects ImageneBio to continue reporting losses but is maintaining a bullish view on the company’s longer-term prospects. ImageneBio Research Coverage Started at HC Wainwright
• Positive Sentiment: Reported short interest fell 87.2% to 49,297 shares as of August 14, representing only 0.4% of shares outstanding. The reduction lowers potential selling pressure and suggests fewer investors are betting against IMA, although the stock’s low trading volume limits the significance of the change.
• Neutral Sentiment: A separate report listed short interest at zero shares as of August 25, unchanged from zero previously. Because the report describes the change as “NaN” and conflicts with the August 14 figures, it appears to be a data-quality issue rather than a meaningful market development.
• Negative Sentiment: HC Wainwright’s detailed forecasts point to continued and potentially widening losses: EPS estimates are negative at $(3.57) for FY2026, $(5.48) for FY2027, and remain negative through FY2030. Persistent cash-burn and the absence of near-term profitability remain important risks, even with the firm’s Buy rating.

ImageneBio Profile

ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025. ImageneBio, Inc is headquartered in San Diego, California.